Bergeson & Campbell,
P.C. is an AV-rated (highest
ranking) Washington, D.C. law firm focusing on conventional and nanoscale
industrial, agricultural, and specialty chemicals
and medical device, product approval and regulation,
product defense, and associated business issues.
Bergeson & Campbell’s
clients are involved in many businesses, including
basic, specialty, and agricultural and antimicrobial
chemicals; biotechnology, nanotechnology, and
emerging transformative technologies; pharmaceuticals,
medical devices, and diagnostic products; fibers;
paints and coatings; printing and publishing;
and plastic products.
We represent and counsel individuals, business entities, trade associations, and industry coalitions. Our professionals conduct advocacy before EPA, FDA, HHS, OSHA, ATSDR, NTP, OMB, the Departments of State, Interior, and U.S. Special Trade Representative, state governmental bodies, federal and state courts, and in other forums, and play active roles in business strategy development, compliance planning, toxic tort defense, acquisitions, and related activities.
Our fundamental goals are to solve our clients' existing problems, and to minimize future difficulties. Reliance on only a single set of skills often is not enough. Legislative opportunities, rulemaking, and litigation options must be coordinated and effectively implemented.
We take a multi-disciplinary approach
in assisting our clients, partnering with toxicological,
chemical, engineering, economic, and other experts
on individual matters as necessary to achieve results
effectively and efficiently. Attention must be paid
to the interplay of all branches of government and
interest groups. Our capabilities, borne of site-
and issue-specific experience, combined with our
national and international view on policy and regulatory
developments, position us to handle all these tasks
with judgment, creativity, and efficiency.
Our activities
are international in scope. They range from confidential
counseling and legislative and administrative representation
to more traditional business, litigation, and arbitration
matters. Our personnel offer extraordinary expertise
in such areas as TSCA, FIFRA, FQPA, FDA, EPCRA,
CAA regulation and enforcement, and
FIFRA data compensation arbitrations. Our personnel
also practice before the CPSC and FTC. Because of the
broad diversity of our subject matter expertise, we
are particularly well-positioned to handle the complex
issues arising from the interactions of environmental
health and safety and food and drug law with the multitude
of other laws affecting our clients. We additionally
offer clients a full range of services to prevent and
defend law suits alleging toxic torts, product liability,
and other claims for liability involving industrial,
specialty, consumer, and agricultural chemical and medical
devices and diagnostic products. On all matters, our
professionals offer experience, judgment, vision, and
vigor.
Lynn
L. Bergeson is a founding member
of Bergeson & Campbell, P.C., in
Washington, D.C. She has practiced
chemicals regulation, environmental, and
occupational safety and health since 1980.
She represents individual corporations
and a wide range of trade associations
on chemical-specific legislative, regulatory,
and enforcement-related matters. Ms. Bergeson's
practice areas include TSCA, FIFRA, EPCRA,
RCRA, CAA, CWA and OSHA compliance and
litigation. Ms. Bergeson is widely published
and lectures frequently on regulatory
and policy issues affecting chemicals
under federal, state, and international
regulatory programs.
Lisa Campbell has practiced
environmental law since 1985. She concentrates on chemicals
regulation and compliance matters under TSCA, FIFRA, RCRA,
OSHA, and other environmental statutes and assists corporations
and trade associations on a wide variety of matters in
these areas. Ms. Campbell writes frequently on chemical
regulatory issues.
Bergeson & Campbell’s consulting
affiliates, The Acta Group, L.L.C. (Acta)
and The Acta Group EU, Ltd (Acta EU),
were established to control the spiraling
costs and inefficiencies encountered by
clients seeking approvals to market chemicals,
products of biotechnology and nanotechnology,
and medical device products. Acta and
Acta EU manage products from concept to
approval, utilizing the skills and experience
of professionals who have worked in the
specific product areas in government and
industry. Acta and Acta EU represent the
following disciplines: regulatory affairs, with particularized expertise with REACH; toxicologists; and government affairs.
Acta and Acta EU professionals have experience
in regulations affecting chemical product
approvals under North American (USA, Canada,
and Mexico), European Union, South American,
Asian, and Pacific Rim regulatory programs.
They regularly track significant legislative,
administrative, and scientific initiatives
that relate to the business of clients
marketing chemicals and medical products
for multiple uses.
The experience and expertise of Acta and Acta EU professionals
cover a wide range of chemicals and products, including
pesticides; industrial and specialty chemicals regulated
under TSCA; products of biotechnology and nanotechnology;
and medical devices. Acta and Acta EU concentrate on obtaining
and maintaining product approvals and overcoming impediments
to the successful and profitable marketing of approved
products. The multi-disciplinary skills possessed by members
of Acta and Acta EU are essential to a cost-effective
and timely product approval project. Today’s regulatory
approvals hinge on the utilization of multiple sources
of information, resources, and skills. Acta and Acta EU
offer a complete line of services intended to take a product
or product concept to the point of its commercial marketing,
to protect the market position of new and existing products,
and to maintain products once they have been approved.
We also make substantial use of non-attorney regulatory
analysts. These professionals provide counseling, monitoring,
project support and direct client assistance on a variety
of federal and state regulatory, legislative, and policy
issues.
